Nkarta (NKTX) Research & Development (2019 - 2026)
Nkarta (NKTX) posted quarterly Research & Development of $25.0 million for Q1 2026, up 3.38% year-over-year from $24.2 million in Q1 2025, and down 1.16% quarter-over-quarter from $25.3 million in Q4 2025.
Nkarta (NKTX) Research & Development (2019 - 2026) Analysis & Trends
Nkarta's Research & Development history runs 8 years deep, the most recent figure standing at $25.0 million for Q1 2026.
- In Q1 2026, Research & Development rose 3.38% year-over-year to $25.0 million; the TTM figure through Mar 2026 stood at $91.2 million (down 4.63% YoY), while the FY2025 annual figure was $90.4 million, down 6.53% from the prior year.
- Research & Development for Q1 2026 stood at $25.0 million, down from $25.3 million in the prior quarter.
- The five-year high for Research & Development was $26.8 million in Q4 2022, with the low at $19.6 million in Q1 2022.
- The 5-year median for Research & Development is $23.4 million (2022), against an average of $23.5 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development surged 55.16% in 2022, then decreased 20.01% in 2025.
- Nkarta's Research & Development stood at $26.8 million in 2022, then dropped by 13.12% to $23.3 million in 2023, then slipped by 0.84% to $23.1 million in 2024, then advanced by 9.31% to $25.3 million in 2025, then slipped by 1.16% to $25.0 million in 2026.
- Business Quant data shows NKTX's Research & Development at $25.0 million in Q1 2026, $25.3 million in Q4 2025, and $20.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 97.90 Mn |
| 10 | Nkarta | 197.41 Mn | 197.41 Mn | - | 29.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.05 Mn |
| Mar 31, 2026 | 24.99 Mn |
| Dec 31, 2025 | 25.28 Mn |
| Sep 30, 2025 | 20.20 Mn |
| Jun 30, 2025 | 20.78 Mn |
| Mar 31, 2025 | 24.17 Mn |
| Dec 31, 2024 | 23.13 Mn |
| Sep 30, 2024 | 25.25 Mn |
| Jun 30, 2024 | 23.13 Mn |
| Mar 31, 2024 | 25.24 Mn |
| Dec 31, 2023 | 23.32 Mn |
| Sep 30, 2023 | 22.19 Mn |
| Jun 30, 2023 | 25.12 Mn |
| Mar 31, 2023 | 26.14 Mn |
| Dec 31, 2022 | 26.84 Mn |
| Sep 30, 2022 | 23.44 Mn |
| Jun 30, 2022 | 21.05 Mn |
| Mar 31, 2022 | 19.57 Mn |
| Dec 31, 2021 | 17.30 Mn |
| Sep 30, 2021 | 16.62 Mn |